| 169 |
Case Study/Series
|
Case series presentation on the use of bi-layered living cell therapy in atypical lower extremity ulcerations First Author: Jeff Karr Authors: Jeffrey C. Karr Among several commercially available bioengineered tissue grafts, there is only one bi-layered living cell therapy* that is approved by the FDA for the use with standard therapeutic compression in the treatment of non-infected partial- and full- thickness venous stasis ulcers as well as full thickness neuropathic diabetic foot ulcers. The bi-layered living cell therapy expresses multiple growth factors found in normal skin, and provides a biologically active matrix. This presentation looks at the possibility of this bi-layered living cell therapy* being beneficial in the management of atypical lower extremity ulcerations. The case series includes a second degree chemical burn involving the foot and ankle, a second degree thermal burn of the foot and ankle, and an ulcer to fibular bone with osteomyelitis and exposed internal fixation. The bi-layered living cell therapy* was an extremely useful in healing this atypical lower extremity ulcers. Significant pain reduction was noted immediately after graft application in the burn cases. The results suggest that bi-layered living cell therapy* is beneficial in atypical lower extremity ulcers. Product notation: *Apligraf¨ is a registered trademark of Organogenesis, Inc, Canton, Mass |
|